FDA Shouldn't Require Monitoring Of Third Parties In REMS, Industry Says

FDA's requirements for Risk Evaluation and Mitigation Strategies should focus on sponsors' activities and not the behavior of third parties, industry tells the agency in comments on a draft guidance